<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02320539</url>
  </required_header>
  <id_info>
    <org_study_id>H-6-2014-073</org_study_id>
    <nct_id>NCT02320539</nct_id>
  </id_info>
  <brief_title>MicroRNA Diagnostics in Subarachnoid Hemorrhage 2</brief_title>
  <official_title>MicroRNA Diagnostics in Subarachnoid Hemorrhage 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate results from a related trial (NCT01791257) and to&#xD;
      compare the profile of microRNA in blood from patients suffering subarachnoid hemorrhage with&#xD;
      and without systemic complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study of patients suffering an aneurysmal subarachnoid hemorrhage (SAH) we would like&#xD;
      to validate former results from CSF studies through microRNA profiling investigate the&#xD;
      pathophysiological mechanisms that lead to systemic complications such as cardiac&#xD;
      dysfunction, acute lung injury (ALI) and systemic inflammatory response syndrome(SIRS).&#xD;
&#xD;
      We will accomplish this through analyzing the profile of microRNA expression in blood and&#xD;
      cerebrospinal fluid from SAH patients.&#xD;
&#xD;
      Validation:&#xD;
&#xD;
      As in our earlier study we wish to compare the expression of 20 specific microRNA between 12&#xD;
      patients developing DCI (group 1) and 12 patients without DCI (group 2) in cerebrospinal&#xD;
      fluid drawn on day 5 after ictus. In addition, some of the patients will have established&#xD;
      invasive neuromonitoring including microdialysis in which we will study changes of certain&#xD;
      microRNAs.&#xD;
&#xD;
      DCI as defined by Vergouwen et al in Stroke 2010;41(10):2391-2395:&#xD;
&#xD;
      &quot;The occurrence of focal neurological impairment (such as hemiparesis, aphasia, apraxia,&#xD;
      hemianopia, or neglect), or a decrease of at least 2 points on the Glasgow Coma Scale (either&#xD;
      on the total score or on one of its individual components [eye, motor on either side,&#xD;
      verbal]). This should last for at least 1 hour, is not apparent immediately after aneurysm&#xD;
      occlusion, and cannot be attributed to other causes by means of clinical assessment, CT or&#xD;
      MRI scanning of the brain, and appropriate laboratory studies.&quot;&#xD;
&#xD;
      Systemic complications:&#xD;
&#xD;
      Furthermore, we wish to compare the expression of 754 specific microRNA in blood drawn on day&#xD;
      3 after ictus between patients with ALI (as described Kahn et al, Crit Care Med. 2006; 34:&#xD;
      196-202) and patients without ALI. Of at least 36 patients expected to be included 12 should&#xD;
      statistically develop ALI according to the referred definition.&#xD;
&#xD;
      Additionally, we wish to compare the expression of 754 specific microRNA between 12 patients&#xD;
      developing DCI (group 1) and 12 patients without DCI (group 2) in blood drawn on day 3 after&#xD;
      ictus.&#xD;
&#xD;
      Moreover, we wish to compare the expression of 754 specific microRNA in blood between 36&#xD;
      patients (group 1-3) to that of healthy controls. The specific microRNAs of interest in which&#xD;
      the expression in blood between patients with systemic complication are analyzed daily to&#xD;
      investigate the dynamic changes in expression and compared to the clinical course.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Delayed Cerebral Ischemia</measure>
    <time_frame>21 days</time_frame>
    <description>Delayed Cerebral Ischemia as defined by Vergouwen et al[1]. In our earlier study we found the clinical condition DCI somehow subjective which is why we added the following two primary outcome measures.&#xD;
Comparing microRNA profiles between groups with or without.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delayed Cerebral Ischemia and Cerebral infarction</measure>
    <time_frame>21 days</time_frame>
    <description>as defined by Vergouwen et al [1].&#xD;
Comparing microRNA profiles between groups with or without.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delayed Cerebral infarction</measure>
    <time_frame>21 days</time_frame>
    <description>as defined by Vergouwen et al [1].&#xD;
Comparing microRNA profiles between groups with or without.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Lung Injury</measure>
    <time_frame>21 days</time_frame>
    <description>as defined by Kahn et al[2].&#xD;
Comparing microRNA profiles between groups with or without</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Dysfunction</measure>
    <time_frame>21 days</time_frame>
    <description>Evaluated by transthoracic echocardiography&#xD;
Comparing microRNA profiles between groups with or without</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Inflammatory Response Syndrome</measure>
    <time_frame>21 days</time_frame>
    <description>Evaluated through daily vital signs and biochemistry&#xD;
Comparing microRNA profiles between groups with or without</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Brain Injury</measure>
    <time_frame>Clinical evaluation 24-72 hours after ictus. (Wake-up call if sedated)</time_frame>
    <description>Early Brain injury = GCS 3-12 and/or paresis (degree 4) of at least one extremity or aphasia No Early Brain injury = GCS 13-15 and no or only small and mild focal deficit&#xD;
Comparing microRNA profiles between groups with or without</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Delayed Cerebral Ischemia</condition>
  <condition>Acute Lung Injury</condition>
  <condition>Cardiac Dysfunction</condition>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <arm_group>
    <arm_group_label>SAH with DCI</arm_group_label>
    <description>After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAH without DCI</arm_group_label>
    <description>After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAH good grade</arm_group_label>
    <description>SAH without external ventricular drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Blood sample in healthy donors registered in the National Donor Registry.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      MicroRNA profiles from blood and cerebrospinal fluid are investigated.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1-2: Patients admitted to Neurointensive Department in Rigshospitalet with SAH&#xD;
        treated with external ventricular drain.&#xD;
&#xD;
        Group 3: Patients admitted to Neurointensive Department in Rigshospitalet with SAH treated&#xD;
        without external ventricular drain.&#xD;
&#xD;
        Group 4: Healthy blood donors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria Group 1-3:&#xD;
&#xD;
          -  Uncertainty &lt; 24 times on time of ictus&#xD;
&#xD;
        Inclusion Criteria Group 1-2:&#xD;
&#xD;
          -  Patients admitted to Neurointensive Department in Rigshospitalet with aneurysmal SAH&#xD;
             treated with external ventricular drain.&#xD;
&#xD;
        Inclusion Criteria Group 3:&#xD;
&#xD;
          -  Patients admitted to Neurointensive Department in Rigshospitalet with aneurysmal SAH&#xD;
             treated without external ventricular drain.&#xD;
&#xD;
        Exclusion Criteria Group 1-3:&#xD;
&#xD;
          -  Transfer to other hospital within 5 days of admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Møller, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Neurointensive Care Unit, The Neuroscience Center, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=20798370</url>
    <description>[1] Vergouwen et al in Stroke 2010;41(10):2391-2395.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/16374174</url>
    <description>[2] Kahn et al, Crit Care Med, Vol. 34, No.1 2006</description>
  </link>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2014</study_first_posted>
  <last_update_submitted>May 25, 2015</last_update_submitted>
  <last_update_submitted_qc>May 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Søren Bache, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>MicroRNA</keyword>
  <keyword>Cerebrospinal fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

